Bayesian estimation of the parameters of the ARCH and GARCH models using lindley's approximation
2016
0 views
0 downloads
Advisor: Prof. Dr. Alexandros Papadopoulos
Abstract (EN)
Autoregressive conditionally heteroscedastic (ARCH) and Generalised ARCH (GARCH) models are used to analyze empirical financial data and capture various stylized facts in financial econometrics. The procedure that is most commonly used for estimating the unknown parameters of ARCH and GARCH model is the maximum likelihood estimation (MLE) method. In this study, it is assumed that the parameters of the ARCH and GARCH models are random variables having known prior probability density functions, and therefore they will be estimated using Bayesian methods. The Bayesian estimators are not in a closed form, and thus Lindley's approximation will be used to estimate them. The Bayesian estimators are derived under squared error loss (SEL) and linear exponential (LINEX) loss functions. Examples are given in order to illustrate the findings. Furthermore, Monte Carlo simulations are performed in order to compare the ML estimates to the Bayesian ones. Finally, conclusions on the findings are given.
Author
Yakup Arı
Institution
How to Cite
Yakup Arı (Doctorate thesis). Bayesian estimation of the parameters of the ARCH and GARCH models using lindley's approximation, 2016, Yeditepe University.
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)